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Abstract

Author Manuscript

Inhibition of specific protein-protein interactions is attractive for a range of therapeutic
applications, but the large and irregularly shaped contact surfaces involved in many such
interactions make it challenging to design synthetic antagonists. Here, we describe the
development of backbone-modified peptides containing both α- and β-amino acid residues (“α/βpeptides”) that target the receptor-binding surface of vascular endothelial growth factor (VEGF).
Our approach is based on the Z-domain, which adopts a three-helix bundle tertiary structure. We
show how a two-helix “mini-Z-domain” can be modified to contain β and other non-proteinogenic
residues while retaining the target-binding epitope using iterative non-natural residue
incorporation. The resulting α/β-peptides are less susceptible to proteolysis than is their parent αpeptide, and some of these α/β-peptides match the full-length Z-domain in terms of affinity for
receptor-recognition surfaces on the VEGF homodimer.

TOC image
α/β-Peptides with a helix-loop-helix tertiary structure that target the receptor-binding surface of
VEGF were developed via an iterative replacement strategy from a starting peptide containing
exclusively proteinogenic residues. This strategy might lead to α/β-peptides that adopt other
tertiary structures.
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Introduction
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Protein-protein interactions represent attractive targets for modulation with designed agents,
for both diagnostic applications and the treatment of disease.[1] Peptides of medium length
can often be developed to bind target proteins with high affinity and selectivity, but if
composition is limited to proteinogenic amino acid residues, then these peptides are highly
susceptible to degradation by proteases.[2] Rapid proteolysis severely limits the applications
of conventional peptides in biological systems. Modifying the peptide backbone, e.g., by
replacing an α-amino acid residue with a β-amino acid residue, protects nearby amide
groups from proteolysis;[2] however, α→β substitutions can also alter folding and
recognition properties relative to the original all-α polypeptide.[3, 4] In recent years it has
been discovered that α/β combinations containing 25–33% β residues distributed along the
backbone can adopt helical conformations that closely mimic the α-helix found in natural
proteins.[3, 5–8] Helical α/β-peptides of this type can mimic the recognition properties of a
natural α-helix, thereby inhibiting protein-protein interactions in which one partner
contributes a single α-helix to the interface, while avoiding rapid destruction by
proteases.[5–10]

Author Manuscript

For many protein-protein interfaces of biomedical interest, each partner contributes a surface
that is large and topologically irregular.[11] Such surfaces often cannot be effectively
engaged by a single α-helix or α-helix-mimic, which would be too narrow to provide
sufficient contact area for strong binding. We speculated that developing ligands for broad
recognition surfaces on target proteins would require advancing the α/β-peptide strategy
beyond mimicry of a lone α-helix. Vascular endothelial growth factor (VEGF) was selected
as a testbed for this effort because of the extensive structural data available for VEGF bound
to fragments of receptor proteins, to antibodies that target the receptor-recognition surface or
to other polypeptide ligands.[12–15] The extent of this structural database reflects the
biomedical significance of disrupting VEGF-receptor interactions.

Author Manuscript

VEGF occurs as a homodimer that binds primarily to two cell-surface receptor tyrosine
kinases, VEGFR1 and VEGFR2, to mediate angiogenesis.[16] (In this report, “VEGF” refers
to the VEGF-A isoform.) Binding of VEGF to its receptors leads to receptor dimerization
and subsequent downstream signaling that promotes the survival, proliferation and migration
of endothelial cells. VEGF signaling through VEGFR2 is thought to be the primary
promotor of angiogenesis, while VEGFR1 is thought to regulate angiogenesis by
sequestering VEGF and other growth factors, although the precise roles of VEGFR1 remain
unclear. Antagonists of the VEGF-VEGFR interaction are currently used to treat various
forms of cancer and wet macular degeneration.[17] The receptor-recognition site on VEGF is
large and topologically irregular, with >800 Å2 of surface on VEGF buried upon binding to a
single receptor (Figure 1A).[12] The large and relatively shallow surfaces that form the
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VEGF-VEGFR interface have made it difficult to develop small molecules to target this
interaction.
Our initial efforts to develop α/β-peptides that bind to the receptor-recognition sites on the
VEGF homodimer were based on a family of disulfide-crosslinked 19-mer peptides
discovered by Fairbrother et al. via phage-display.[18] An NMR-derived structure of the
peptide designated v107 bound to the VEGF homodimer revealed that the 19-mer adopts a
specific but largely non-helical conformation (Figure 1B).[15] We found that implementing
α→β replacements in this scaffold could enhance resistance to proteolysis, but that these
replacements caused an erosion in affinity for VEGF.[19] These observations led us to seek
VEGF-binding peptides with higher α-helical content.

Author Manuscript

In 2011, Fedorova et al. reported a 59-residue peptide that adopts a three-helix-bundle
tertiary structure and binds to the receptor-recognition sites on the VEGF homodimer (ZVEGF, Figure 1C and Figure 2).[14] This engineered ligand was based on the “Z-domain”;
the parent Z-domain peptide binds to a specific site on IgG via a broad surface formed by αhelices 1 and 2 of the three-helix bundle.[20] The Z-domain scaffold has become a popular
basis for developing ligands for a variety of target proteins via screening of phage-display
libraries in which residues on the composite helix 1+helix 2 surface are varied.[21, 22] In
recent human clinical trials Z-domain-based imaging agents that target HER2 have been
evaluated for diagnosis of breast cancer.[23]

Author Manuscript

We saw Z-VEGF as a potential starting point for developing an α/β-peptide that could block
VEGF-mediated signaling and avoid rapid proteolysis. Specifically, we envisioned following
the lead of Wells et al.[24, 25] to truncate the Z-domain to a disulfide-crosslinked helix-loophelix tertiary structure that retained the binding surface that had been optimized via phagedisplay, and then incorporating unnatural residues into the distal sides of the helices (relative
to the VEGF-recognition epitope). We have already described the final outcome of this
effort, in which both β-amino acid residues and Aib residues were employed to generate a
39-mer α/β-peptide that retained high affinity for VEGF but displayed much less
susceptibility to proteolysis than did Z-VEGF, the 59-residue parent Z-domain.[26] The
resulting α/β scaffold proved amenable to the grafting of contact α-amino acid residues
specific for other protein targets, to generate new α/β-peptides that retained the binding
specificities of their parent Z-domain analogues.
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Here we describe the design path that led to the optimized anti-VEGF α/β-peptides recently
described.[26] We document an iterative strategy for identifying sites that tolerate α→β
residue replacement without compromising affinity for VEGF. This approach is distinct
from prior efforts to transform α-helical α-peptides into α/β-peptides with comparable
conformations and binding properties, which have focused primarily on regular patterns of
α→β-amino acid residue substitution implemented throughout the entire sequence. Those
prior efforts were limited to mimicry of an isolated secondary structure (a single helix),
while the approach that delivered high-affinity VEGF-binding α/β-peptides had to
accommodate a specific tertiary structure. The challenges of implementing backbone
modifications in the context of a discrete tertiary structure are highlighted by a recently
described D-α-amino acid scan of a disulfide-crosslinked, two-helix Z-domain
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derivative;[27] single L→D residue replacements at most of the sites led to a dramatic
decline in affinity for the target protein (IgG). We speculate that the principles illustrated by
the iterative development process documented here may prove to be useful for generating
target-specific α/β-peptide ligands based on other tertiary structures.

Results
Design of two-helix analogues of Z-VEGF
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Z-VEGF (Figure 2) is a 59-residue three-helix peptide that was developed by Fedorova et
al. by randomizing 9 residues on helices 1 and 2 of the Z-domain scaffold via phage display,
followed by selection for binding to the VEGF8-109 dimer.[14] A co-crystal structure of ZVEGF with VEGF8-109 shows that the engineered Z-domain adopts the expected three-helix
bundle tertiary structure and engages the receptor-recognition sites on the VEGF dimer
through a surface formed by helices 1 and 2 of Z-VEGF (Figure 1C).[14] We hypothesized
that α/β-peptide analogues of Z-VEGF might function as VEGF antagonists. Furthermore,
because only helix 1 and helix 2 of Z-VEGF make contact with VEGF in the co-crystal
structure, we sought to generate a two-helix α/β-peptide analogue that would mimic the
helix 1-loop-helix 2 motif within the Z-VEGF tertiary structure.

Author Manuscript
Author Manuscript

Only residues 7–58 of the 59-mer ligand appear in the Z-VEGF+VEGF8-109 co-crystal
structure.[14] For several other engineered Z-domains that bind to diverse protein partners,
removal of N-terminal residues has a negligible effect on affinity for the target.[24, 25, 28]
These precedents suggested to us that residues 1–6 of Z-VEGF might not be required for
high-affinity binding to VEGF. We tested this hypothesis by evaluating the truncated αpeptide Z-VEGF(7-56) for binding to VEGF165. Affinity was assessed with a competition
fluorescence polarization (FP) assay that we previously described, involving displacement of
a fluorescently labelled peptide known to bind to the receptor-recognition surfaces on the
VEGF165 dimer.[29] Full-length Z-VEGF displayed an equilibrium dissociation constant
(Ki) of 0.41 μM in this assay, while Ki = 5.8 μM for Z-VEGF(7-56) (Figure 2, Figure S1).
(See Figure S1 for derivation of Ki values and a discussion of experimental uncertainty in FP
measurements.) The ~14-fold decline in affinity for VEGF165 resulting from these
seemingly modest changes were surprising in light of reports that target affinity had been
largely retained after more dramatic truncations of engineered Z-domains that engage other
proteins.[24, 25, 28] The diminished affinity of Z-VEGF(7-56) suggests that the terminal
residues of the 59-mer somehow encourage complexation with VEGF, despite being
unresolved in the Z-VEGF+VEGF8-109 co-crystal structure. Efforts to design truncated and
conformationally-constrained analogues of Z-VEGF(7-56) proved only modestly successful
(Figure S2).
To ask whether residues 1–6 and 57–59 exert a large effect on the conformation of Z-VEGF,
we compared the far-UV circular dichroism (CD) spectrum of this 59-mer with the data for
Z-VEGF(7-56) (Figure 3). Both α-peptides displayed strong minima at ~208 nm and 222
nm, as expected for conformations that feature primarily α-helical secondary structure. The
per-residue CD spectra of these two polypeptides overlay very closely, which suggests that
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residues 1–6 and 57–59 do not exert a strong influence on the extent of α-helicity in ZVEGF.
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In light of the results obtained with peptide Z-VEGF(7-56), we designed two-helix
analogues of Z-VEGF that retained residues 1–6 (Figure 2). As previously reported,[26] ZVEGF(1-38) showed no detectable binding to VEGF. Since removal of helix 3 was expected
to reduce conformational stability, as seen in prior truncation efforts based on Z-domain
analogues,[24, 25, 28] we next incorporated five α-amino acid residue substitutions that had
previously been identified by phage display[24, 28] as stabilizing for a helix-loop-helix
tertiary fold. For our Z-VEGF-based design, structural alignment of Z-VEGF with a twohelix IgG-targeting Z-domain analogue[25] dictated these replacements to be Tyr13→Arg,
Ile17→Ala, Leu20→Asp, Phe31→Lys and Leu35→Ile. These substitutions, along with a
Met9→Gln substitution to avoid undesired oxidation, yielded α-VEGF-1 (Figure 2). The
substitution at position 9 was based on a two-helix, disulfide-stabilized IgG-binding Zdomain analogue that contains Gln at the equivalent position.[24, 25] However, in contrast to
prior Z-domain analogue truncation efforts,[24, 25, 28] we observed that the incorporation of
these helix-stabilizing substitutions did not cause recovery of protein affinity in the absence
of helix 3, as α-VEGF-1 did not show any affinity for VEGF in the competition FP assay
(Figure 2).

Author Manuscript

In an attempt to further stabilize the intended helix 1-loop-helix 2 tertiary structure, we next
incorporated a disulfide bond into the design of our two-helix Z-VEGF analogues (peptides
1 and 2, Figure 2), a strategy that has been previously successful for other two-helix Zdomain analogues.[25, 28] The residues for cysteine replacement were chosen based on
structural alignment of the Z-VEGF crystal structure[14] with the solution NMR structure of
a two-helix, disulfide-constrained Z-domain analogue targeting IgG.[25] This alignment
showed that His10 and Pro39 lie at the positions in the helix1-helix 2 segment of Z-VEGF
that correspond to the oxidized cysteine residues in the two-helix IgG-targeting Z-domain
analogue. Our design included a glycine residue at the C-terminus as a spacer between the
linker to the solid support and the last cysteine residue during solid-phase peptide synthesis.
A C-terminal Gly is found also in other peptides described below. This feature was included
in an effort to maximize synthesis yields.

Author Manuscript

We found that α-peptides 1 and 2, which are the disulfide-constrained analogues of ZVEGF(1-38) and α-VEGF-1, respectively, bind to VEGF165 with affinity comparable to
that of the Z-VEGF 59-mer (Figure 2). α-Peptide α-VEGF-2, which differs from 2 only in
lacking the C-terminal Gly residue, bound to VEGF with affinity comparable to that of 2,
according to the competition FP assay. This result indicates that the C-terminal Gly of 2 has
a negligible effect in terms of binding to VEGF.
Iterative incorporation of β-amino acid residues and Aib residues based on scaffold
peptide 2
α-Peptide 2 was used as the starting point for a systematic evaluation of α→β residue
substitutions with the goal of generating α/β-peptides that bind tightly to VEGF but are
minimally susceptible to proteolysis. We have previously shown that the substitution of α
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residues with the homologous β3 residues (bearing the same side chain, Figure 4B) in an
ααβαααβ pattern can generate α/β-peptides that structurally and functionally mimic
isolated α-helices that are recognized by specific partner proteins.[6, 9, 30] Based on these
precedents, we asked whether this pattern of substitutions in a single helix of the helix-loophelix tertiary structure would be tolerated in the present system. α/β-Peptide 3 contains three
α→β3 substitutions in positions that are predicted not to make contact intermolecularly with
VEGF or intramolecularly with helix 1 (Figure 4); these substitution sites should occur on
the solvent-exposed face of the peptide when bound to VEGF. This α/β-peptide, however,
showed very little affinity for VEGF according to the FP assay (Figure 4, Figure S1).
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Incorporation of β3-amino acid residues into helical structures can sometimes lead to a
decreased affinity for target proteins, likely due to the increased backbone flexibility of a β3
residue relative to an α residue (a β3 residue contains one more bond with a low torsional
barrier relative to an α residue).[5, 31] In such cases, the incorporation of cyclicallyconstrained β-amino acid residues such as ACPC, APC or sAPC (Figure 4B) sometimes
increases affinity,[10, 32] presumably by restricting the Cα-Cβ torsion. We therefore
implemented single cyclic β residue substitutions at solvent-exposed positions of helix 2,
replacing uncharged Ala30 or Ser34 with ACPC, to give α/β-peptides 4 and 5, respectively.
α/β-Peptide 4 showed very low affinity for VEGF by FP (Ki > 40 μM), while 5 showed
significant affinity (Ki = 0.99 μM). α/β-Peptide 6, which contains both the Ala30→ACPC
and Ser34→ACPC substitutions, showed very weak binding to VEGF (Ki > 100 μM). These
data suggest that some solvent-exposed positions in helix 2, such as position 34, can tolerate
α→cyclic β replacement but others, such as position 30, cannot.

Author Manuscript

Our next designs explored the use of Aib residues rather than β residues as nonproteinogenic substitutions. Aib has a strong helical propensity,[33] and this residue can
hinder the action of proteases at nearby peptide bonds,[34] although less effectively than
α→β substitutions.[31] Peptide 7, which contains three Aib residues, bound to VEGF with
high affinity (Ki = 0.23 μM), possibly because Aib residues at these positions increase the
helicity of the two-helix peptide. α/β-Peptide 8, which contains the Ala30→ACPC
substitution in addition to two Aib substitutions, showed very low affinity for VEGF,
mirroring the results from 4 and 6, which also place ACPC at position 30. However, α/βpeptide 9, which contains the Ser34→ACPC substitution in addition to two Aib residue
replacements, showed high affinity for VEGF (Ki = 0.17 μM).

Author Manuscript

We used 9 as a starting point for additional replacements into the C-terminal end of helix 2
and into helix 1. Peptides 10 and 11 contain an Asp→sAPC substitution, which preserves
the acidic side chain, in addition to those substitutions in 9. Both showed substantial affinity
for VEGF, but 11 bound more tightly (Ki = 0.061 μM for 11 versus 0.48 μM for 10),
indicating that the Asp37→sAPC substitution is more favorable than Asp38→sAPC. In a
parallel set of studies based on 9 we examined non-natural substitutions into helix 1. Peptide
12 has an Aib substitution at position 12, and 13 has Aib substitutions at positions 9 and 12;
both bound VEGF with affinity comparable to that of 9. α/β-Peptides 14 and 15 were
prepared to evaluate α→cyclic β residue substitution at positions 9 or 12. Both of these sites
proved amenable to these modifications, and α/β-peptide 16, containing ACPC at both sites
and the Asp37→sAPC substitution identified above, bound to VEGF with high affinity (Ki
Chembiochem. Author manuscript; available in PMC 2018 February 01.
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= 0.072 μM in the competition FP assay). The building block for the sAPC residue requires
multistep organic synthesis, but Fmoc-(S,S)-ACPC is commercially available; therefore, we
examined 17, which contains ACPC at position 37. α/β-Peptide 17 showed affinity for
VEGF that was comparable to affinity displayed by 16.
We next sought to evaluate which residues at the N-terminus of α/β-peptide 17 were
necessary for tight binding to VEGF. An analogue of 17 lacking residues 1–3 bound tightly
to VEGF (α/β-peptide 18, Ki = 0.19 μM), but a significant drop in affinity was observed
when residues 1–6 were removed (α/β-peptide 19, Ki = 3.8 μM).
Protease stability assays

Author Manuscript

α/β-Peptide 16 incorporates four α→cyclic β and two Aib substitutions, each of which may
reduce this oligomer’s susceptibility to protease degradation.[5, 10, 34] To evaluate this
susceptibility, we incubated 40 μM of 16 with 10 μg/mL proteinase K, a promiscuous and
aggressive protease,[35] and quantified the amount of intact oligomer remaining by high
performance liquid chromatography (HPLC) (Figure 5, Figure S3). A parallel evaluation
was conducted with α-peptide α-VEGF-2 to provide a basis for comparison.

Author Manuscript

α-VEGF-2 was rapidly degraded by proteinase K and displayed a half-life of 0.24 minutes
in this assay. In contrast, α/β-peptide 16 displayed a half-life of 68 minutes under the same
conditions (>280-fold increase in half-life relative to α-VEGF-2), which is consistent with
our prediction that multiple α→cyclic β and Aib substitutions scattered across the sequence
should discourage protease action. We examined several quenched aliquots from the reaction
of 16 with proteinase K by matrix-assisted laser desorption ionization time of flight mass
spectrometry (MALDI-TOF MS) to identify cleavage sites based on observation of masses
that correspond to hypothetical products of peptide bond hydrolysis (Figure S4). Although
we were not able to assign every fragment in the MALDI-TOF spectra, we identified masses
that correspond to products resulting from hydrolysis of the Gln26-Gln27 amide bond and
the Lys7-Glu8 amide bond for the proteinase K digestion of 16 (Figure 6, red arrows). These
results suggest that 16 may be most susceptible to proteolysis near the central loop in helix 2
(Gln26-Gln27) and near the N-terminus (Lys7-Glu8).
Final α/β-peptide designs

Author Manuscript

Closely related α/β-peptides 16 and 17 showed high affinity for VEGF, and 16 was
significantly less susceptible to protease degradation than was the parent α-peptide, αVEGF-2. However, the high number of hydrophobic ACPC and Aib residues incorporated
into 17–19 may encourage non-specific interactions with other proteins when these peptides
are introduced into biological systems. In an effort to reduce hydrophobicity, we prepared
20, the analogue of 17 that contains basic APC residues in place of hydrophobic ACPC
residues at positions 12 and 34 (Figure 6). In addition, 20 differs from 17 in lacking the Cterminal Gly residue. The affinity of α/β-peptide 20 for VEGF proved to be
indistinguishable from the affinity of 17 (Ki = 0.10 μM for 20).
Our final design goal was to incorporate additional non-proteinogenic residues into the two
regions of 20 containing long stretches of α residues, the N-terminus and the central loop, to
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discourage protease action in these regions. Because there is no high-resolution structural
information regarding possible interactions between the N-terminal segment and VEGF, we
focused on α→β3 replacements, which preserve the original side chains. The molecule
previously designated α/β-VEGF-1 contains two such replacements, at positions 2 and 5,
and binds to VEGF with affinity indistinguishable from that of 16, 17 or 20 (Ki for α/βVEGF-1 = 0.11 μM, Figure 6).[26] An analogue of α/β-VEGF-1 lacking residues 1–3, α/βpeptide 21, displayed comparable affinity for VEGF (Ki = 0.15 μM); this observation is
consistent with the binding similarities for 17 and 18.

Author Manuscript

The region from Ala18 to His29 in α/β-VEGF-1 contains only proteinogenic α-amino acid
residues, and the proteolysis experiment described above suggested that the region near
Gln26-Gln27 may be particularly susceptible to proteolysis (Figure 5, Figure S4). Therefore,
we examined α/β-peptides 22, α/β-VEGF-2, and 23, which are, respectively, the analogues
of 20, α/β-VEGF-1, and 21, that contain the Gln26→Aib substitution (Figure 6).[34] The
three new α/β-peptides each manifested substantial affinity for VEGF (Ki = 0.34–0.46 μM).
These α/β-peptides bound slightly less tightly than did α/β-VEGF-1, but they were
experimentally indistinguishable in terms of VEGF binding from the full-length α-peptide
Z-VEGF and the parent two-helix α-peptide α-VEGF-2. As predicted, α/β-VEGF-2
manifested significantly reduced susceptibility to proteinase K digestion relative to other
compounds evaluated in this series, with a half-life of 670 minutes, as previously
reported.[26]

Author Manuscript
Author Manuscript

To determine whether the disulfide crosslink is important for binding of our α/β-peptides to
VEGF we evaluated α/β-VEGF-1-LIN, the analogue of α/β-VEGF-1 that contains the
native residue from Z-VEGF (His) in place of the Cys10 and lacks Cys39 (Figure 6). α/βVEGF-1-LIN showed very little affinity for VEGF in the competition FP assay (Ki > 50
μM). The far UV-CD spectrum of α/β-VEGF-1-LIN in PBS, pH 7.5 showed a single
minimum at ~206 nm, which is characteristic of helical secondary structure among α/βpeptides (Figure 7).[3, 36] However, the intensity of the normalized CD minimum for α/βVEGF-1-LIN was weaker and blue-shifted relative to that of disulfide-crosslinked analogue
α/β-VEGF-1 (Figure 7A). Changes in the CD spectrum of the type observed upon
transformation of α/β-VEGF-1 to α/β-VEGF-1-LIN have previously been observed[3] for
α/β-peptide modifications that appear to diminish the extent of helix formation. The weaker
intensity of the CD minimum for α/β-VEGF-1-LIN relative to α/β-VEGF-1 suggests that
the crosslink in α/β-VEGF-1 enhances the helicity of this α/β-peptide in aqueous solution.
The intensity of the CD minimum for α/β-VEGF-1 in water changes little upon 10-fold
dilution from 50 μM to 5 μM (Figure 7B), which suggests that the secondary structure of this
α/β-peptide is not highly dependent on peptide aggregation.

Discussion
The primary motivation for creating an α/β-peptide mimic of a protein-binding α-peptide is
to retain high affinity for the target protein while significantly diminishing susceptibility to
proteolysis. Most previous efforts of this type have begun with α-peptides that form a single,
long α-helix, over most or all of the sequence, when bound to the target.[32] In several
different systems, success has been achieved with α/β-peptides in which α→β replacement
Chembiochem. Author manuscript; available in PMC 2018 February 01.

Checco and Gellman

Page 9

Author Manuscript

sites occur in simple patterns (αααβ or ααβαααβ) that provide 25–33% β residue content
and disperse the β residues along the backbone.[5, 6, 9, 30, 31] α/β-Peptides with this β residue
density typically display substantial resistance to proteolysis, particularly if cyclic β residues
are employed. Furthermore, initial data suggest that such α/β-peptides may generally evade
immunological recognition. Specifically, α/β-peptides containing multiple α→β
replacements were not recognized by antibodies raised against the analogous α-peptides,
and this type of α/β-peptide bound poorly to an MHC.[37] However, further studies are
necessary to develop a more complete understanding of α/β-peptide interactions with the
immune system.

Author Manuscript

Most α/β-peptides evaluated to date for inhibition of a protein-protein interaction mimic a
single α-helix, but many protein-protein interfaces of interest are characterized by broader
surfaces than can be effectively targeted by a single α-helix.[11] Complexes involving the
receptor-recognition surfaces on the VEGF homodimer are representative of this type of
expansive target. We sought to identify an α/β-peptide scaffold that would transcend an
isolated helix.

Author Manuscript

The development described here of α/β-peptides that bind to the receptor-recognition
surface of VEGF was inspired by the demonstration by Fedorova et al.[14] that the threehelix-bundle Z-domain scaffold could be used to generate α-peptides that target VEGF. The
prospect of truncating from three to two helices[24, 25] provided further motivation because
~40-mers are significantly more tractable synthetically than are ~60-mers. In addition, a
two-helix tertiary structure is more favorable than the three-helix tertiary structure in terms
of maximizing the density of α→β substitutions. Multi-helix modules offer a greater
challenge than does an isolated α-helix in terms of the placement of β residues or other nonproteinogenic residues, particularly if the new residues do not maintain the original side
chain, as is the case with a cyclic β residue or Aib. Replacement sites in a multi-helix
module must be chosen to avoid disrupting intermolecular contacts with the target protein,
and also to avoid disrupting intramolecular contacts that are critical for folding. Starting
from a full-length Z-domain derivative such as Z-VEGF, the most obvious positions for
α→β substitution occur on the solvent-exposed side of helix 3. For helices 1 and 2, side
chains from many of the solvent-exposed residues make contacts with VEGF, and
replacements at these sites could therefore be deleterious to binding. For each of the three
helices of Z-VEGF, α→β replacements at sites that pack against another helix in the native
state could diminish tertiary structural stability. In contrast, a two-helix analogue presents a
larger proportion of favorable opportunities for α→β substitution because both helices have
a ‘back face’ that would be exposed to solvent in the VEGF-bound state.

Author Manuscript

The considerations outlined above led us to conclude that an iterative strategy would be
necessary for identifying positions in a helix-loop-helix tertiary structure that could
accommodate non-proteinogenic residues and for determining which type of nonproteinogenic residue could be accommodated (cyclic β vs. Aib). An iterative, site-by-site
approach would contrast with the approach previously used to generate α/β-peptides that
mimic isolated α-helices. This latter goal has been achieved by exploring small sets of α/βpeptides in which each registry of a repeating α/β pattern is evaluated, e.g., all four registries
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that are possible for the αααβ pattern, or all seven registries that are possible for the
ααβαααβ pattern.[5, 6, 9, 30]
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Having identified α-peptide 2 as a disulfide-crosslinked mini-Z-domain with high affinity
for VEGF, we sought to identify sites that would tolerate β and/or Aib substitutions. Initial
efforts focused on a relatively small number of positions identified that neither contact
VEGF8-109 in the co-crystal structure with the full-length Z-domain nor are expected to be
involved in intramolecular packing of the helices against one another. Affinity for VEGF
was used to assess tolerance of substitution at the selected sites, only some of which proved
amenable to substitution with a cyclic β and/or Aib residue. Once a set of candidate sites had
been vetted in this way, the highest-affinity analogue was used as the starting point for
evaluating a new set of potential substitution sites. At an intermediate stage in this iterative
process (α/β-peptide 16, which contains four cyclic β residues and two Aib residues), we
conducted a protease digestion assay to identify the regions of highest susceptibility to
cleavage. As expected, proteolytic susceptibility was most pronounced in segments
comprising multiple consecutive α residues. Placement of additional β and Aib residues in
these segments was accomplished in a manner that largely preserved affinity for VEGF
while enhancing resistance to degradation. This iterative development process ultimately
provided α/β-peptides α/β-VEGF-1 and α/β-VEGF-2, high-affinity ligands for VEGF that
are substantially less susceptible to proteinase K degradation relative to the parent α-peptide
(α-VEGF-2) and even relative to the original three-helix α-peptide Z-VEGF.[26]
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Although the positions of the non-proteinogenic residues for the iterative non-natural residue
incorporation were selected based on the Z-VEGF+VEGF8-109 co-crystal structure,[14] our
findings show that crystallographic information does not necessarily provide all of the
insight a designer might require for rational design of high-affinity protein-binding peptides.
For example, the lack of electron density for Z-VEGF residues 1–6 in the co-crystal
structure led us to postulate that this segment was not important for binding to VEGF, but
experimental results invalidated this hypothesis. In addition, the Z-VEGF+VEGF8-109 cocrystal structure suggested that the Ala30 side chain does not make contact with VEGF or
participate in tertiary packing; however, placement of cyclic β residue ACPC at this position
caused a substantial loss in affinity for VEGF. In contrast, Aib was tolerated at position 30.
The apparent requirement for an α residue at this site was not readily deduced from the
crystallographic data.

Author Manuscript

The strategy that culminated in development of α/β-VEGF-1 and α/β-VEGF-2, proteaseresistant oligomers with an unnatural backbone that bind tightly to a protein target of high
biomedical significance, is important because these α/β-peptides achieve an unprecedented
molecular engineering goal. Previously described α/β-peptide antagonists have mimicked
isolated α-helices, but the examples described here recapitulate a more complex folding
pattern. Identifying replacement sites among the original proteinogenic residues has required
us to accommodate not only points of contact with the target surface on VEGF but also
intramolecular packing interactions. The difficulty of this engineering challenge is
highlighted by a recently reported D-residue scan of a 33-residue peptide derived from the
Z-domain.[27] This fundamental study revealed that substitution of a single L-α residue with
its enantiomer at the majority of positions caused a profound decline in affinity for the target
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protein (an IgG fragment). The sites most tolerant of L→D residue replacement were mainly
near the termini. No diastereomeric peptides containing more than one L→D replacement
were reported, but the available data suggest that most multiple-replacement patterns would
cause a substantial loss of affinity for the target and of the native helix-loop-helix tertiary
structure. In light of these findings for heterochiral α-peptide analogues of Z-domainderived motif, the ability we have demonstrated to generate helix-loop-helix analogues that
contain multiple β-amino acid and Aib residues distributed across the sequence, and that
retain high affinity for VEGF, for TNFα or for IgG,[26] demonstrates the potential power of
this approach for engineering polypeptide binding agents that resist enzymatic degradation.
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Although we were drawn to a Z-domain-derived tertiary structure as our starting point
because of the copious α-helical secondary structure, the iterative replacement strategy
illustrated here should, in principle, be applicable to poly-α-peptides with alternative tertiary
structures. However, additional examples will be required in order to determine whether this
strategy is truly general. It is encouraging that Horne et al.[38] have shown that non-natural
residue substitutions can be tolerated within a tertiary structure that contains β-sheet in
addition to α-helix secondary structure. Modules that have been used to develop binding
agents for biomedically important proteins would be of particular interest for such
efforts.[22]

Experimental Section
Materials

Author Manuscript

Fmoc-protected α-amino acids with compatible side-chain protecting groups and
benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) were
purchased from Chem-Impex International and Novabiochem. Fmoc-protected β3-amino
acids with compatible side-chain protecting groups were purchased from PepTech
Corporation and Chem-Impex International. Fmoc-ACPC-OH was purchased from ChemImpex International (15073). Fmoc-sAPC(OtBu)-OH was synthesized as previously
described.[10b] Fmoc-APC(Boc)-OH was synthesized as previously described.[39]
Peptide synthesis and purification

Author Manuscript

α- and α/β-Peptides were synthesized on NovaPEG Rink Amide resin (Novabiochem,
855047) using microwave-assisted solid-phase conditions, as previously described,[26] or
using a Symphony automated peptide synthesizer (Protein Technologies). During microwave
synthesis, coupling reactions were carried out with a solution of Fmoc-protected amino acid
activated with PyBOP, 0.1 M 1-hydoxybenzotriazole (HOBt), and N,Ndiisopropylethylamine (DIEA) in 1-methyl-2-pyrrolidone (NMP). Fmoc deprotection
reactions were carried using a solution of 5% piperazine, 0.1 M HOBt in N,Ndimethylformamide (DMF). After the final Fmoc deprotection reaction, α- and α/β-peptides
were cleaved from the resin using a cleavage solution of 95% trifluoroacetic acid (TFA),
2.5% H2O, and 2.5% triisopropylsilane for oligomers with no cysteine residues and a
cleavage solution of 94% TFA, 2.5% H2O, 2.5% ethanedithiol, and 1% triisopropylsilane for
oligomers with cysteine residues. All peptides contain a free N-terminal amine. Cleavage
solutions were concentrated under N2, and then peptides were precipitated with cold diethyl
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ether. For peptides with no disulfide bond, crude peptide mixtures were then subjected to
purification by reverse-phase HPLC. For peptides with a disulfide bond, crude peptide
mixtures were dissolved in a solution of dimethylsulfoxide (DMSO) (~10 mL DMSO for a
50 μmol resin loading) and ammonium hydroxide (~25 drops for a 50 μmol resin loading).
These DMSO solutions were exposed to air to allow the peptides to oxidize over several
days (4–7 days), followed by purification by reverse-phase HPLC. Alternatively, disulfidecontaining peptides could also be purified as the bis-thiol immediately after cleavage (in the
presence of reducing agent TCEP), subjected to oxidation using the above conditions,
followed by repurification by HPLC.
Protein expression
VEGF165 was expressed and purified as previously reported.[29]
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VEGF fluorescence polarization assays

Author Manuscript

Direct binding and competition fluorescence polarization assays were performed as
previously described using the previously reported tracer, BODIPY-v114*ΔNT (Sequence =
(BODIPYTMR)-X-CDIHV(Nle)WEWECFERL-NH2, where X = [2-(2-amino-ethoxy)ethoxy]acetic acid, (Nle) = norleucine, and cysteines are linked in intramolecular disulfide,
reported Kd = 21 nM).[19, 26, 29] To account for slight variations in the activity of protein
solutions resulting from different VEGF165 expressions, the Kd for the tracer was
experimentally determined for each new VEGF165 stock (using direct-binding mode),[29]
and this Kd used to determine Ki values in the resulting competition FP assays using that
VEGF165 expression. Briefly, DMSO stock solutions of potential inhibitors were prepared
and their concentration determined by UV absorbance at 280 nm.[40] Competition FP assays
were performed by adding 2 μL of potential inhibitor in DMSO to 48 μL of a solution
containing VEGF165 and tracer (Final conditions = 40 nM VEGF165, 10 nM tracer in 50 mM
NaCl, 16.2 mM Na2HPO4, 3.8 mM KH2PO4, 0.15 mM NaN3, 0.15 mM EDTA, 0.5 mg/mL
Pluronic-F68, pH 7.5). Plates were covered from light and incubated at room temperature for
5–7 hours, and then read on either an Envision 2100 or a BioTek Synergy 2 microplate
reader. Inhibition constants (Ki) were calculated from FP data using a competitive binding
model[41] in GraphPad Prism 4.0. See Figure S1 for all FP data, fitted Ki values, and a
discussion of Ki fitting and an estimation of experimental uncertainty.
Circular Dichroism (CD)

Author Manuscript

CD experiments were carried out on a Aviv Model 420 CD Spectrometer. Solutions of
peptide were prepared in PBS, pH 7.5 or pure water at approximately 75 μM or 50 μM, with
the exact concentration determined by UV-absorbance.[40] Spectra were collected in a 0.1
cm quartz cuvette, a 1 nm wavelength step size, a 10 second averaging time, and at 20 °C.
For measurement at 5 μM, the 50 μM solution was diluted 10-fold in water and a spectrum
was collected in a 1 cm quartz cuvette. Spectra were normalized to units of [θ] (deg cm2
dmol−1 res−1) × 10−3. Spectra for Z-VEGF and α/β-VEGF-1 were previously reported in
the Supporting Information of Checco et al.,[26] but are displayed here for comparison.
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Proteinase K stability assay
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Proteinase K digestions were performed as previously described, with slight
modifications.[26] Briefly, peptide stocks were prepared in TBS, pH 7.5 with 10% DMSO at
80 μM, as determined by UV absorbance.[40] A stock solution of 50 μg/mL proteinase K
(Novagen 70663-4) was prepared in TBS, pH 7.5 (without DMSO). Peptide stocks were
diluted and proteinase K stock solution was added to give final concentrations of 40 μM
peptide, 10 μg/mL proteinase K, 5% DMSO in TBS, pH 7.5 and the reaction was allowed to
proceed at room temperature. Reactions were run in duplicate. At each time point, 50 μL of
the protease reaction was quenched with 100 μL of 50% acetonitrile in water with 1% TFA,
and 125 μL of this quenched solution was injected onto analytical scale reverse-phase
HPLC. The amount of peptide remaining, relative to the “0 minute” time point, was
determined by integration of the peak at 220 nm in the resulting chromatogram
corresponding to the intact peptide. Half-lives were determined by fitting the time course of
degradation of intact peptide to an exponential decay model in GraphPad Prism 4.0.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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High-resolution structures of VEGF (grey) in complex with A) domain 2 of VEGFR1
(orange), B) phage-derived peptide v107 (teal), and C) Z-domain analogue Z-VEGF
(yellow).
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Figure 2.

Primary sequences of two-helix α-peptides derived from Z-VEGF derivatives, along with
associated Ki values, as determined by VEGF165 competition FP assay. Each cysteine is
engaged in an intramolecular disulfide bond. Ki values marked with a * are values
previously reported for these compounds.[26] See Figure S1 for derivation of Ki values and a
discussion of experimental uncertainty in FP measurements.
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Figure 3.
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Far-UV CD spectrum for Z-VEGF (7-56) (blue) at 75 μM in PBS, pH 7.5. The previously
reported spectrum for Z-VEGF (red) is shown for comparison.[26]
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Figure 4.
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A) Primary sequences of α/β-peptide derivatives of 2 and α-VEGF-2, along with associated
Ki values, as determined by VEGF165 competition fluorescence polarization (FP) assay.
Non-natural residues are indicated by colored circles. Each cysteine is engaged in an
intramolecular disulfide bond. Ki values marked with a * are values previously reported for
these compounds.[26] B) Structures of a generic α residue, the Aib residue (green), a generic
β3 residue (teal), and the cyclic β residues ACPC, APC, and sAPC (orange). See Figure S1
for derivation of Ki values and a discussion of experimental uncertainty in FP measurements.
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Figure 5.

Susceptibility of 40 μM α-peptide α-VEGF-2 and α/β-peptide 16 to 10 μg/mL proteinase K
in TBS, pH 7.5 with 5% DMSO at room temperature. Red arrows indicate early cleavage
sites for α/β-peptide 16, as assessed by MALDI-TOF MS of the reaction mixture after 64
minutes.
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Figure 6.
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Primary sequences of α/β-peptide derivatives of 16 and 17, along with associated Ki values,
as determined by VEGF165 competition fluorescence polarization (FP) assay. Non-natural
residues are indicated by colored circles, as depicted in Figure 4B. Each cysteine is engaged
in an intramolecular disulfide bond. Ki values marked with a * are values previously
reported for these compounds.[26] See Figure S1 for derivation of Ki values and a discussion
of experimental uncertainty in FP measurements.
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Figure 7.
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A) Far-UV CD spectrum for α/β-VEGF-1-LIN (blue) at 75 μM in PBS, pH 7.5. The
previously reported spectrum for α/β-VEGF-1 (red) is shown for comparison.[26] B) FarUV CD spectra for α/β-VEGF-1 at 50 μM (red) or 5 μM (blue) in water.
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